Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Safety and Efficacy of RGH-188 (Cariprazine) in Bipolar Depression

ClinicalTrials.gov ID: NCT00852202

Public ClinicalTrials.gov record NCT00852202. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 3, 2026, 7:51 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Double-blind, Placebo-controlled Study of RGH-188 (Cariprazine) in Bipolar Depression

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to evaluate the efficacy, safety, and tolerability of cariprazine in the treatment of outpatients with bipolar depression.

Study identification

NCT ID
NCT00852202
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Forest Laboratories
Industry
Enrollment
234 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years to 65 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jun 29, 2009
Primary completion
Jun 14, 2010
Completion
Jun 14, 2010
Last update posted
Aug 22, 2018

2009 – 2010

United States locations

U.S. sites
26
U.S. states
15
U.S. cities
26
Facility City State ZIP Site status
Forest Investigative Site 005 Encino California 91316
Forest Investigative Site 017 Garden Grove California 92845
Forest Investigative Site 027 National City California 91950
Forest Investigative Site 013 Newport Beach California 92660
Forest Investigative Site 010 Oceanside California 92056
Forest Investigative Site 020 Bradenton Florida 34208
Forest Investigative Site 007 Jacksonville Florida 32216
Forest Investigative Site 019 Kissimmee Florida 34741
Forest Investigative Site 026 Orlando Florida 32806
Forest Investigative Site 012 West Palm Beach Florida 33407
Forest Investigative Site 024 Glen Burnie Maryland 21061
Forest Investigative Site 029 Creve Coeur Missouri 63141
Forest Investigative Site 002 Omaha Nebraska 68131
Forest Investigative Site 028 Cherry Hill New Jersey 08002
Forest Investigative Site 001 The Bronx New York 10467
Forest Investigative Site 018 Durham North Carolina 27710
Forest Investigative Site 004 Dayton Ohio 45417
Forest Investigative Site 022 Mason Ohio 45040
Forest Investigative Site 015 Portland Oregon 97210
Forest Investigative Site 006 Media Pennsylvania 19063
Forest Investigative Site 011 Philadelphia Pennsylvania 19107
Forest Investigative Site 014 Nashville Tennessee 37212
Forest Investigative Site 023 Irving Texas 75062
Forest Investigative Site 003 Woodstock Vermont 05091
Forest Investigative Site 009 Bellevue Washington 98004
Forest Investigative Site 016 Seattle Washington 98104

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00852202, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Aug 22, 2018 · Synced Sep 3, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00852202 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →